

**DESCRIPTION**

<b>Source</b>	Human embryonic kidney cell, HEK293-derived cynomolgus monkey Siglec-2/CD22 protein		
	Cynomolgus Monkey Siglec-2/CD22 (Asp20-Arg687) Accession # EHH59463	IEGRMD	Human IgG <sub>1</sub> (Pro100-Lys330)
	N-terminus		C-terminus
<b>N-terminal Sequence Analysis</b>	Asp20		
<b>Structure / Form</b>	Disulfide-linked homodimer		
<b>Predicted Molecular Mass</b>	102 kDa		

**SPECIFICATIONS**

<b>SDS-PAGE</b>	115-134 kDa, reducing conditions
<b>Activity</b>	Measured by the ability of the immobilized protein to support the adhesion of human red blood cells. Kelm, S. <i>et al.</i> (1994) Current Biology 4:965. The ED <sub>50</sub> for this effect is 0.07-0.42 µg/mL.
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the protein by the LAL method.
<b>Purity</b>	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 250 µg/mL in PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<p><b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b></p> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 3 months, ≤ -20 °C under sterile conditions after reconstitution.</li> </ul>

**DATA**

**Bioactivity**

Recombinant Cynomolgus Monkey Siglec-2/CD22 Fc Chimera (Catalog # 10031-SL) supports the adhesion of human red blood cells. The ED<sub>50</sub> for this effect is 0.07-0.42 µg/mL.

**SDS-PAGE**

2 µg/lane of Recombinant Cynomolgus Monkey Siglec-2/CD22 Fc Chimera was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 115-134 kDa and 230-270 kDa, respectively.

**BACKGROUND**

Siglecs are sialic acid specific I-type lectins that are characterized by an extracellular domain (ECD) with an N-terminal Ig-like V-type domain followed by varying numbers of Ig-like C2-type domains (1, 2). Siglec-2, also known as B cell antigen CD22 or B-lymphocyte cell adhesion molecule (BL-CAM), is a B cell restricted glycoprotein that is expressed in the cytoplasm of progenitor B and pre-B cells and on the surface of mature B cells. In humans, two distinct Siglec-2 cDNAs that arise from differential RNA processing of the same gene have been isolated. The predominant Siglec-2 (Isoform CD22-beta) encodes an 847 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-terminal Ig-like V-type domain, six Ig-like C2-type domains, a transmembrane region and a cytoplasmic tail with four immunoreceptor tyrosine-based inhibition motifs (ITIMs) (3). The variant Siglec-2 (Isoform CD22-alpha) encodes a 647 aa polypeptide missing two Ig-like C2-type domains and has a truncated (23 aa) cytoplasmic tail (4). Within the ECD, cynomolgus Siglec-2 shares 84%, 55%, and 56% aa sequence identity with human, mouse, and rat Siglec-2, respectively. Siglec-2 is an adhesion molecule that preferentially binds alpha 2,6- linked sialic acid on the same (*cis*) or adjacent (*trans*) cells. Interaction of Siglec-2 with *trans* ligands on opposing cells is found to be favored over the binding of ligands *in cis* (5). Consistent with a single ligand-binding region, the first two N-terminal Ig-like domains mediated CD22 adhesion with lymphocytes, neutrophils, monocytes, and erythrocytes (6). Besides its role as an adhesion molecule, Siglec-2 is a co-receptor that physically interacts with B cell receptor (BCR) and is rapidly phosphorylated upon BCR ligation. It negatively regulates BCR signals by recruiting tyrosine phosphatase SHP-1 to its ITIMs. Phosphorylated Siglec-2 can also interact with other intracellular effector proteins such as Syk, PLC gamma, PI3 kinase and Grb-2, suggesting it may play a role in positive signaling (7, 8).

**References:**

1. Varki, A. and T. Angata (2006) *Glycobiology* **16**:1R.
2. Crocker, P.R. *et al.* (2007) *Nat. Rev. Immunol.* **7**:255.
3. Wilson, G.L. *et al.* (1991) *J. Exp. Med.* **173**:137.
4. Stamenkovic, I. and B. Seed (1990) *Nature* **345**:74.
5. Collins, B.E. *et al.* (2004) *Proc. Natl. Acad. Sci.* **101**:6104.
6. Engel, P. *et al.* (1995) *J Exp Med.* **181**:1581
7. Ravetch, J.V. and L.L. Lanier (2000) *Science* **290**:84.
8. Wienands, Y.J. *et al.* (1999) *J. Biol. Chem.* **274**:18769.